{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:57:55Z","timestamp":1774331875950,"version":"3.50.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1001\/jamacardio.2019.1049","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T15:42:01Z","timestamp":1556120521000},"page":"515","source":"Crossref","is-referenced-by-count":61,"title":["Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm"],"prefix":"10.1001","volume":"4","author":[{"given":"Barry","family":"Greenberg","sequence":"first","affiliation":[{"name":"Cardiology Division, Department of Medicine, University of California, San Diego, La Jolla"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Neaton","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Berlin\u2013Brandenburg Center for Regenerative Therapies, Berlin, Germany"},{"name":"Department of Cardiology, German Center for Cardiovascular Research partner site Berlin, Charite Universitatsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Byra","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G. F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, Scotland"},{"name":"National Heart and Lung Institute, Imperial College London, London, England"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiaowei","family":"Deng","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"La Police","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore, Singapore"},{"name":"Duke-National University of Singapore, Singapore"},{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Nessel","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore E.","family":"Spiro","sequence":"additional","affiliation":[{"name":"Research and Development, Pharmaceuticals, Thrombosis and Hematology Therapeutic Area, Bayer US, Whippany, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Vanden Boom","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universite de Lorraine, INSERM Unite 1116, Vandoeuvre les Nancy, France"},{"name":"Clinical Investigation Center 1433, French Clinical Research Infrastructure Network, Investigation Network Initiative\u2013Cardiovascular and Renal Clinical Trialists, Centre Hospitalier Regional et Universitaire de Nancy, Vandoeuvre les Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"hoi190018r1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome.","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"hoi190018r2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease.","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"hoi190018r3","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.amjcard.2018.08.034","article-title":"Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 Trial).","volume":"122","author":"Korjian","year":"2018","journal-title":"Am J Cardiol"},{"issue":"14","key":"hoi190018r5","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease.","volume":"379","author":"Zannad","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi190018r6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.amjmed.2008.08.026","article-title":"\u201cDose-dependent\u201d impact of recurrent cardiac events on mortality in patients with heart failure.","volume":"122","author":"Lee","year":"2009","journal-title":"Am J Med"},{"issue":"15","key":"hoi190018r7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2011.1474","article-title":"National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008.","volume":"306","author":"Chen","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"hoi190018r8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"hoi190018r9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","article-title":"Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.","volume":"116","author":"Solomon","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"hoi190018r10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1161\/CIRCHEARTFAILURE.110.959957","article-title":"Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions.","volume":"4","author":"Bettari","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"6","key":"hoi190018r11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","article-title":"Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial.","volume":"102","author":"Uretsky","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"hoi190018r12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJM199701233360403","article-title":"Ventricular dysfunction and the risk of stroke after myocardial infarction.","volume":"336","author":"Loh","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi190018r13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/01.CIR.92.7.1701","article-title":"Sudden coronary death: frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction.","volume":"92","author":"Farb","year":"1995","journal-title":"Circulation"},{"issue":"11","key":"hoi190018r14","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jamacardio.2018.3285","article-title":"Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study.","volume":"3","author":"Acharya","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"23","key":"hoi190018r15","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2009.07.042","article-title":"Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death: relation to epicardial plaque histopathology.","volume":"54","author":"Schwartz","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"hoi190018r16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0021-9150(00)00598-0","article-title":"Coronary atherosclerosis in unheralded sudden coronary death under age 50: histo-pathologic comparison with 'healthy' subjects dying out of hospital.","volume":"155","author":"Schmemund","year":"2001","journal-title":"Atherosclerosis"},{"issue":"7","key":"hoi190018r17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ejhf.266","article-title":"Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.","volume":"17","author":"Zannad","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"408","key":"hoi190018r18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.","volume":"84","author":"Wei","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"hoi190018r19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0735-1097(98)00006-0","article-title":"Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction.","volume":"31","author":"Al-Khadra","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi190018r20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejheart.2006.02.012","article-title":"Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.","volume":"8","author":"Cokkinos","year":"2006","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"hoi190018r21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ahj.2004.03.010","article-title":"The Warfarin\/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure.","volume":"148","author":"Cleland","year":"2004","journal-title":"Am Heart J"},{"issue":"12","key":"hoi190018r22","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/CIRCULATIONAHA.108.801753","article-title":"Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.","volume":"119","author":"Massie","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"hoi190018r23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1056\/NEJMoa1202299","article-title":"Warfarin and aspirin in patients with heart failure and sinus rhythm.","volume":"366","author":"Homma","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi190018r24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1161\/01.CIR.81.3.772","article-title":"Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy.","volume":"81","author":"Treasure","year":"1990","journal-title":"Circulation"},{"issue":"2","key":"hoi190018r25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurheartj\/14.2.205","article-title":"Platelet function, thrombin and fibrinolytic activity in patients with heart failure.","volume":"14","author":"Jafri","year":"1993","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi190018r26","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/S0735-1097(99)00033-9","article-title":"Does heart failure confer a hypercoagulable state? Virchow\u2019s triad revisited.","volume":"33","author":"Lip","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"hoi190018r27","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1161\/01.CIR.103.13.1746","article-title":"Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy.","volume":"103","author":"Gibbs","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"hoi190018r28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.healun.2010.08.027","article-title":"Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.","volume":"30","author":"Gheorghiade","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"hoi190018r4","author":"Branch"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/6\/515\/17664507\/jamacardiology_greenberg_2019_oi_190018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T15:01:16Z","timestamp":1560956476000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.1049"}},"subtitle":["A Post Hoc Analysis of the COMMANDER HF Trial"],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.1049","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}